Cargando…
Arctigenin Treatment Protects against Brain Damage through an Anti-Inflammatory and Anti-Apoptotic Mechanism after Needle Insertion
Convection enhanced delivery (CED) infuses drugs directly into brain tissue. Needle insertion is required and results in a stab wound injury (SWI). Subsequent secondary injury involves the release of inflammatory and apoptotic cytokines, which have dramatic consequences on the integrity of damaged t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916177/ https://www.ncbi.nlm.nih.gov/pubmed/27445818 http://dx.doi.org/10.3389/fphar.2016.00182 |
_version_ | 1782438782149066752 |
---|---|
author | Song, Jie Li, Na Xia, Yang Gao, Zhong Zou, Sa-feng Kong, Liang Yao, Ying-Jia Jiao, Ya-Nan Yan, Yu-Hui Li, Shao-Heng Tao, Zhen-Yu Lian, Guan Yang, Jing-Xian Kang, Ting-Guo |
author_facet | Song, Jie Li, Na Xia, Yang Gao, Zhong Zou, Sa-feng Kong, Liang Yao, Ying-Jia Jiao, Ya-Nan Yan, Yu-Hui Li, Shao-Heng Tao, Zhen-Yu Lian, Guan Yang, Jing-Xian Kang, Ting-Guo |
author_sort | Song, Jie |
collection | PubMed |
description | Convection enhanced delivery (CED) infuses drugs directly into brain tissue. Needle insertion is required and results in a stab wound injury (SWI). Subsequent secondary injury involves the release of inflammatory and apoptotic cytokines, which have dramatic consequences on the integrity of damaged tissue, leading to the evolution of a pericontusional-damaged area minutes to days after in the initial injury. The present study investigated the capacity for arctigenin (ARC) to prevent secondary brain injury and the determination of the underlying mechanism of action in a mouse model of SWI that mimics the process of CED. After CED, mice received a gavage of ARC from 30 min to 14 days. Neurological severity scores (NSS) and wound closure degree were assessed after the injury. Histological analysis and immunocytochemistry were used to evaluated the extent of brain damage and neuroinflammation. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was used to detect universal apoptosis. Enzyme-linked immunosorbent assays (ELISA) was used to test the inflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-10) and lactate dehydrogenase (LDH) content. Gene levels of inflammation (TNF-α, IL-6, and IL-10) and apoptosis (Caspase-3, Bax and Bcl-2) were detected by reverse transcription-polymerase chain reaction (RT-PCR). Using these, we analyzed ARC’s efficacy and mechanism of action. Results: ARC treatment improved neurological function by reducing brain water content and hematoma and accelerating wound closure relative to untreated mice. ARC treatment reduced the levels of TNF-α and IL-6 and the number of allograft inflammatory factor (IBA)- and myeloperoxidase (MPO)-positive cells and increased the levels of IL-10. ARC-treated mice had fewer TUNEL+ apoptotic neurons and activated caspase-3-positive neurons surrounding the lesion than controls, indicating increased neuronal survival. Conclusions: ARC treatment confers neuroprotection of brain tissue through anti-inflammatory and anti-apoptotic effects in a mouse model of SWI. These results suggest a new strategy for promoting neuronal survival and function after CED to improve long-term patient outcome. |
format | Online Article Text |
id | pubmed-4916177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-49161772016-07-21 Arctigenin Treatment Protects against Brain Damage through an Anti-Inflammatory and Anti-Apoptotic Mechanism after Needle Insertion Song, Jie Li, Na Xia, Yang Gao, Zhong Zou, Sa-feng Kong, Liang Yao, Ying-Jia Jiao, Ya-Nan Yan, Yu-Hui Li, Shao-Heng Tao, Zhen-Yu Lian, Guan Yang, Jing-Xian Kang, Ting-Guo Front Pharmacol Pharmacology Convection enhanced delivery (CED) infuses drugs directly into brain tissue. Needle insertion is required and results in a stab wound injury (SWI). Subsequent secondary injury involves the release of inflammatory and apoptotic cytokines, which have dramatic consequences on the integrity of damaged tissue, leading to the evolution of a pericontusional-damaged area minutes to days after in the initial injury. The present study investigated the capacity for arctigenin (ARC) to prevent secondary brain injury and the determination of the underlying mechanism of action in a mouse model of SWI that mimics the process of CED. After CED, mice received a gavage of ARC from 30 min to 14 days. Neurological severity scores (NSS) and wound closure degree were assessed after the injury. Histological analysis and immunocytochemistry were used to evaluated the extent of brain damage and neuroinflammation. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was used to detect universal apoptosis. Enzyme-linked immunosorbent assays (ELISA) was used to test the inflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-10) and lactate dehydrogenase (LDH) content. Gene levels of inflammation (TNF-α, IL-6, and IL-10) and apoptosis (Caspase-3, Bax and Bcl-2) were detected by reverse transcription-polymerase chain reaction (RT-PCR). Using these, we analyzed ARC’s efficacy and mechanism of action. Results: ARC treatment improved neurological function by reducing brain water content and hematoma and accelerating wound closure relative to untreated mice. ARC treatment reduced the levels of TNF-α and IL-6 and the number of allograft inflammatory factor (IBA)- and myeloperoxidase (MPO)-positive cells and increased the levels of IL-10. ARC-treated mice had fewer TUNEL+ apoptotic neurons and activated caspase-3-positive neurons surrounding the lesion than controls, indicating increased neuronal survival. Conclusions: ARC treatment confers neuroprotection of brain tissue through anti-inflammatory and anti-apoptotic effects in a mouse model of SWI. These results suggest a new strategy for promoting neuronal survival and function after CED to improve long-term patient outcome. Frontiers Media S.A. 2016-06-22 /pmc/articles/PMC4916177/ /pubmed/27445818 http://dx.doi.org/10.3389/fphar.2016.00182 Text en Copyright © 2016 Song, Li, Xia, Gao, Zou, Kong, Yao, Jiao, Yan, Li, Tao, Lian, Yang and Kang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Song, Jie Li, Na Xia, Yang Gao, Zhong Zou, Sa-feng Kong, Liang Yao, Ying-Jia Jiao, Ya-Nan Yan, Yu-Hui Li, Shao-Heng Tao, Zhen-Yu Lian, Guan Yang, Jing-Xian Kang, Ting-Guo Arctigenin Treatment Protects against Brain Damage through an Anti-Inflammatory and Anti-Apoptotic Mechanism after Needle Insertion |
title | Arctigenin Treatment Protects against Brain Damage through an Anti-Inflammatory and Anti-Apoptotic Mechanism after Needle Insertion |
title_full | Arctigenin Treatment Protects against Brain Damage through an Anti-Inflammatory and Anti-Apoptotic Mechanism after Needle Insertion |
title_fullStr | Arctigenin Treatment Protects against Brain Damage through an Anti-Inflammatory and Anti-Apoptotic Mechanism after Needle Insertion |
title_full_unstemmed | Arctigenin Treatment Protects against Brain Damage through an Anti-Inflammatory and Anti-Apoptotic Mechanism after Needle Insertion |
title_short | Arctigenin Treatment Protects against Brain Damage through an Anti-Inflammatory and Anti-Apoptotic Mechanism after Needle Insertion |
title_sort | arctigenin treatment protects against brain damage through an anti-inflammatory and anti-apoptotic mechanism after needle insertion |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916177/ https://www.ncbi.nlm.nih.gov/pubmed/27445818 http://dx.doi.org/10.3389/fphar.2016.00182 |
work_keys_str_mv | AT songjie arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT lina arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT xiayang arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT gaozhong arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT zousafeng arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT kongliang arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT yaoyingjia arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT jiaoyanan arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT yanyuhui arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT lishaoheng arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT taozhenyu arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT lianguan arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT yangjingxian arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion AT kangtingguo arctigenintreatmentprotectsagainstbraindamagethroughanantiinflammatoryandantiapoptoticmechanismafterneedleinsertion |